Tower Research Capital (TRC)’s PDL BioPharma, Inc. PDLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-49,918
| Closed | -$123K | – | 6072 |
|
|
2020
Q4 | $123K | Sell |
49,918
-143,836
| -74% | -$350K | ﹤0.01% | 2156 |
|
|
2020
Q3 | $610K | Buy |
193,754
+133,229
| +220% | +$426K | 0.01% | 1470 |
|
|
2020
Q2 | $176K | Buy |
60,525
+57,180
| +1,709% | +$181K | 0.01% | 1901 |
|
|
2020
Q1 | $9K | Buy |
3,345
+664
| +25% | +$2.14K | ﹤0.01% | 2102 |
|
|
2019
Q4 | $8K | Sell |
2,681
-6,147
| -70% | -$17.8K | ﹤0.01% | 2489 |
|
|
2019
Q3 | $19K | Buy |
8,828
+8,528
| +2,843% | +$22.8K | ﹤0.01% | 2527 |
|
|
2019
Q2 | $1K | Sell |
300
-32
| -10% | -$104 | ﹤0.01% | 3576 |
|
|
2019
Q1 | $1K | Buy |
+332
| New | +$1.12K | ﹤0.01% | 3711 |
|
|
2018
Q4 | – | Sell |
-4,890
| Closed | -$13K | – | 4800 |
|
|
2018
Q3 | $13K | Sell |
4,890
-3,680
| -43% | -$9.03K | ﹤0.01% | 2633 |
|
|
2018
Q2 | $20K | Buy |
8,570
+1,295
| +18% | +$3.62K | ﹤0.01% | 2454 |
|
|
2018
Q1 | $21K | Buy |
7,275
+2,548
| +54% | +$6.96K | ﹤0.01% | 2164 |
|
|
2017
Q4 | $13K | Sell |
4,727
-960
| -17% | -$2.95K | ﹤0.01% | 2419 |
|
|
2017
Q3 | $19K | Buy |
5,687
+2,684
| +89% | +$7.46K | ﹤0.01% | 2773 |
|
|
2017
Q2 | $7K | Buy |
+3,003
| New | +$6.91K | ﹤0.01% | 1861 |
|
|
2016
Q3 | – | Sell |
-958
| Closed | -$3K | – | 5253 |
|
|
2016
Q2 | $3K | Sell |
958
-3,342
| -78% | -$11.1K | ﹤0.01% | 3831 |
|
|
2016
Q1 | $14K | Sell |
4,300
-7
| -0.2% | -$22 | ﹤0.01% | 1675 |
|
|
2015
Q4 | $15K | Buy |
+4,307
| New | +$18K | ﹤0.01% | 1662 |
|
|
2015
Q2 | – | Sell |
-99
| Closed | -$1K | – | 5686 |
|
|
2015
Q1 | $1K | Sell |
99
-2,964
| -97% | -$21.5K | ﹤0.01% | 4319 |
|
|
2014
Q4 | $23K | Buy |
3,063
+3,058
| +61,160% | +$24.2K | ﹤0.01% | 1521 |
|
|
2014
Q3 | $0 | Sell |
5
-95
| -95% | -$882 | ﹤0.01% | 5449 |
|
|
2014
Q2 | $1K | Sell |
100
-5,986
| -98% | -$53.4K | ﹤0.01% | 3917 |
|
|
2014
Q1 | $51K | Buy |
6,086
+5,888
| +2,974% | +$50.5K | 0.01% | 1089 |
|
|
2013
Q4 | $2K | Sell |
198
-13,252
| -99% | -$112K | ﹤0.01% | 4155 |
|
|
2013
Q3 | $107K | Buy |
+13,450
| New | +$108K | 0.01% | 1235 |
|
Other funds holding PDLI
Tower Research Capital (TRC)'s PDLI Position: Q1 2021 in Review
Tower Research Capital (TRC) sold out of PDL BioPharma, Inc. (PDLI) in Q1 2021, closing a stake of 49,918 shares — an estimated $123K sold.
Tower Research Capital (TRC) first reported a position in PDLI in Q3 2013 and held it in 24 quarters. The position peaked at $610K in Q3 2020. 11 funds tracked by Wall St. Rank hold PDLI as of Q1 2021.
- Tower Research Capital (TRC) reported no remaining PDL BioPharma, Inc. position as of Q1 2021 after selling out during the quarter.
- Tower Research Capital (TRC) sold 49,918 PDL BioPharma, Inc. shares in Q1 2021, an estimated $123K.
- Tower Research Capital (TRC) first reported a position in PDL BioPharma, Inc. in Q3 2013 and held it in 24 quarters.
- Tower Research Capital (TRC)'s PDL BioPharma, Inc. position peaked at $610K in Q3 2020.
- 11 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2021.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2021, filed 17 May 2021.